{name}
{subtitle}
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~12 mi. (Würzburg, Germany, +130 more cities)
facility
Universitaetsklinikum Wuerzburg ( Site 0265)
drug
BCG solution, +1 more drug
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~12 mi. (Würzburg, Germany, +199 more cities)
facility
Universitaetsklinikum Wuerzburg ( Site 0468)
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
city
~12 mi. (Würzburg, Germany, +141 more cities)
facility
GSK Investigational Site
drug type
chemotherapy, +1 more type
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
city
~12 mi. (Würzburg, Germany, +74 more cities)
facility
GSK Investigational Site
drug
belantamab mafodotin, +3 more drugs
drug type
chemotherapy, +2 more types
Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma
city
~12 mi. (Würzburg, Germany, +18 more cities)
facility
Universitätsklinikum Würzburg - Klinik für Dermatologie, Venerologie und Allergologie